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Abstract.
Background: Genetic variation in Spondin-1, specifically rs11023139, has been associated with reduced rates of cognitive
decline in individuals with Alzheimer’s disease.
Objective: The aim of this study was to assess whether the association was present in cognitively normal older adults.
Methods: Longitudinal cognitive decline was investigated using linear mixed modelling in a cohort of 590 cognitively normal
older adults enrolled in the Australian Imaging, Biomarkers and Lifestyle Study.
Results: No independent effect of Spondin-1 rs11023139 on cognitive decline was observed. However, significant associations
were observed for the interaction between Apolipoprotein E (APOE) ε4 and rs11023139 in individuals with high amyloid-
burden. APOE ε4/rs11023139-A carriers declined significantly faster than APOE ε4/rs11023139-G G carriers in measures
of global cognition (p = 0.011) and verbal episodic memory (p = 0.020).
Conclusion: These results suggest that carriage of the Spondin-1 rs11023139-A allele significantly contributes to a worsening
of cognitive performance in APOE ε4 cognitively normal older adults with a high neocortical amyloid- burden.
Keywords: Alzheimer’s disease, amyloid-, APOE, cognitive decline, SPON1, Spondin-1
INTRODUCTION
Alzheimer’s disease (AD) is characterized by
significant impairment in memory and cognition,
which occurs gradually as the disease progresses [1].
Deterioration in cognition can also be observed in
cognitively normal (CN) older adults, particularly
those with evidence of pathological changes char-
acteristic of AD, such as an elevated neocortical
amyloid- (A) burden [2, 3], a feature included
in the National Institute on Aging and Alzheimer’s
Association (NIA/AA) recommended criteria for pre-
clinical AD [4]. Although the presence of abnormally
high levels of A and tau, which define the pre-
clinical AD stage, are associated with subtle decline
in cognition, there remains substantial between per-
son variability in the rate of this decline, suggesting
other biological factors may act to influence this.
Understanding these rates of change in cognition in
preclinical AD and how they are influenced will not
only assist with the development of disease interven-
tion strategies but will also significantly contribute
to furthering our understanding of the genesis of the
disease itself.
In preclinical AD, rates of cognitive change have
previously been shown to be influenced by genetic
factors. Particularly, allelic variations within the
genes encoding apolipoprotein E (ApoE; APOE)
[5–7], brain derived neurotropic factor (BDNF) [8,
9], and Kidney and Brian expressed protein (KIBRA)
[10] have all been associated with differences in cog-
nitive performance over time at this stage of the dis-
ease. Cognitive domains known to deteriorate early in
the disease process, i.e., episodic memory, have been
observed to be influenced significantly by genetic
variation.
In a genome-wide association study (GWAS) for
the Alzheimer’s Disease Assessment Scale–cognitive
subscale (ADAS-Cog) performance in the Alzhei-
mer’s Disease Neuroimaging Initiative (ADNI), an
association of rs11023139, within the Spondin-1 (F-
Spondin; SPON1) gene located on chromosome 11
(11p15.5), in those clinically diagnosed with AD
(though in the absence of reported A status) was
identified [11]. The study found associations of the
minor allele (A) with reduced rates of decline on the
ADAS-Cog and on subsequent analysis with reduced
rates of decline on the Rey Auditory Verbal Learning
Test (RAVLT) and Mini-Mental State Examination
(MMSE) [11]. Spondin-1 is an extracellular matrix
protein involved in the growth of axons during embry-
onic development [12, 13], differentiation of neural
cells [14], and the promotion of axonal regenera-
tion post-injury [15]. Overexpression of Spondin-1 in
the brains of wild type and AD-transgenic mice has
been associated with improvements in spatial learn-
ing and memory, and the reduction of A plaque
load [16]. Spondin-1 has also been implicated in
pathways involved in AD pathology. Specifically, it
was identified in a screen of proteins interacting with
amyloid- protein precursor (APP) in vivo [17]. In
particular, Spondin-1 has been shown to bind to the
extracellular domain of APP inhibiting its cleavage
by beta-secretase [18].
As the previous study linking SPON1 rs11023139
with cognitive performance was undertaken at the
advanced clinical stages of AD [11], the aim of this
current study was to determine whether this asso-
ciation with cognitive decline was also present in
the preclinical stages of AD. In this context the
relationship between SPON1 rs11023139 and pre-
clinical A-related cognitive decline can be assessed
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in the absence of several potential confounds, includ-
ing the influence of: consequent disease processes
(e.g., inflammation, vascular deterioration), substan-
tial generalized diminished intellectual ability that
occurs in dementia that may reduce the reliability
of cognitive assessment, or potential floor effects of
cognitive assessments that may reduce sensitivity to
any acceleration of disease related change in cogni-
tion. The hypothesis of the study was that SPON1
rs11023139 would exert a modifying effect on A
and APOE ε4 mediated cognitive decline. To address
these research questions longitudinal cognitive data,
collected as part of the Australian Imaging, Biomark-
ers and Lifestyle Study of Aging (AIBL) was utilized.
This study focused on cognitively normal older adults
with known neocortical A burden.
MATERIALS AND METHODS
Participants
Participants for the study described here included
590 CN older adults recruited as part of the larger
AIBL Study, for which information regarding enrol-
ment, neuropsychological assessment and diagnostic
criteria has been previously published [19]. Follow-
up assessment occurred every 18-months, with 7.5
years of longitudinal data being utilized in this study.
All assessments (neuropsychological, imaging, and
laboratory) for each time-point were acquired within
3-months of each other. Ethics approval had been
granted for the AIBL Study by all member institu-
tions; Austin Health, St Vincent’s Health, Hollywood
Private Hospital, and Edith Cowan University, and
informed written consent was provided by all
participants.
Cognitive measures
All 18-monthly AIBL study follow-ups involve
neuropsychological, clinical and intelligence testing
as previously described [19]. The AIBL neuropsy-
chological test battery consists of the following;
MMSE, Clock Drawing Test, California Verbal
Learning Test-Second edition (CVLT-II), Logical
Memory I and II (LMI; LMII; Story A only), D-KEFS
verbal fluency, the 30-item version of the Boston
Naming Test (BNT), Wechsler Test of Adult Read-
ing (WTAR) for premorbid IQ, Digit Span and Digit
Symbol-Coding subtests of the Wechsler Adult Intel-
ligence Scale-Third edition (WAIS-III), the Stroop
task (Victoria version), and the Rey Complex Figure
Test (RCFT). In addition, data from the Clinical
Dementia Rating (CDR), Geriatric Depression Scale
(GDS), and WTAR-estimated premorbid IQ (WAIS-
III Full Scale Intelligence Quotient (FSIQ)) were
collected. Previously calculated cognitive compos-
ite scores, aiming to measure preclinical cognitive
performance, were utilized in the current study [20,
21]. Burnham et al. developed a statistically derived
composite measures of global cognition (CDRSB,
MMSE, LMII, CVLTFP, and Clock) and verbal
episodic memory (CDR sum of boxes (CDRSB),
LMII, CVLT false positives (CVLTFP) and long delay
free recall (CVLTLDFR)), both of which were cor-
rected for age, gender, years of education, premorbid
IQ and depressive symptoms [20]. Donohue et al.
have previously published the Pre-Alzheimer’s cog-
nitive composite (PACC (CVLT-II, LMII, MMSE,
WAIS-III subscales)), which acted as an additional
measure of global cognition specific to preclinical
AD [21].
Amyloid-β imaging
As described previously [22–24], study partici-
pants underwent A imaging with positron emission
tomography (PET) using 11C-Pittsburgh Compound
B (PiB), 18F-florbetapir or 18F-flutemetamol radi-
olabelled tracers. Generation of PET standardized
uptake value (SUV) ratio (SUVR) data was through
the use of CapAIBL, a web based freely availably
MR-less methodology [25]. SUVs were summed and
normalized to areas specific to the radiolabelled tracer
used. That is, cerebellar cortex SUV for PiB, whole
cerebellum SUV for florbetapir or pons SUV for
flutemetamol, thus generating the target-region to
reference-region SUVRs. The current study utilized
a binary low (Alow) or high (Ahigh) A burden
classification. This classification was determined by
a participant’s SUVR being higher than the tracer-
specific threshold at any time point for which they
were imaged. The tracer-specific SUVR thresholds
utilized in this study are; ≥ 1.5, ≥ 1.10 and ≥ 0.62
for PiB, florbetapir and flutemetamol, respectively, as
previously described [26].
Genotyping
A 5 ml aliquot of whole blood taken as part of the
AIBL protocol [19] and was utilized for DNA extrac-
tion and subsequent single nucleotide polymorphism
(SNP) genotyping, as previously described [10,
27–29]. QIAamp DNA Blood Maxi Kits (Qiagen,
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Table 1
Demographic Information
Overall n = 590 SPON1A– n = 531 SPON1A+ n = 59 p
Age [y], mean (SD) 70.87 (6.45) 70.75 (6.42) 71.71 (6.28) 0.2743
Female, n (%) 327 (55.42) 288 (54.24) 39 (66.10) 0.1093
Years of Education, n (%) 0–8 46 (7.82) 41 (7.74) 5 (8.62) 0.8405
9–12 216 (36.73) 194 (36.63) 22 (37.93)
13–15 124 (21.09) 110 (20.75) 14 (24.14)
15+ 202 (34.35) 185 (34.91) 17 (29.31)
Premorbid IQ [FSIQ], mean (SD) 108.00 (7.24) 107.84 (7.30) 108.98 (6.85) 0.2567
Depressive Symptoms [GDS], mean (SD) 1.06 (1.27) 1.06 (1.29) 0.98 (1.13) 0.6781
APOE ε4 carriage, n (%) 167 (28.31) 153 (28.81) 14 (23.73) 0.5027
High amyloid- burden, n (%) 254 (43.05) 223 (42.00) 31 (52.54) 0.1575
Baseline demographic and clinical characteristics of all imaged cognitively normal adults in the AIBL study and based on SPON1 rs11023139
A carriage (SPON1A+; A A and G A) and non-carriage (SPON1A–; G G). p values represent statistical significance when comparing
SPON1A– and SPON1A+. SPON1, Spondin-1; APOE, Apolipoprotein E; FSIQ, Wechsler Adult Intelligence Scale 3rd Edition (WAIS-III)
Full Scale Intelligence Quotient; GDS, Geriatric Depression Scale.
Hilden, Germany) were used for DNA extraction
and TaqMan® genotyping assays (Life Technolo-
gies, Carlsbad, CA) for APOE (rs7412, assay ID:
C 904973 10; rs429358, assay ID: C 3084793 20)
and SPON1 (rs11023139, assay ID: C 55174 30)
genotyping. TaqMan® genotyping assays were
performed using the QuantStudio 12K Flex™ Real-
Time-PCR systems (Applied Biosystems, Foster
City, CA) and TaqMan® GTXpress™ Master Mix
(Life Technologies). Methodologies outlined in the
manufacturer’s instructions were followed for kits
and assays detailed above.
Data analyses
All analyses detailed in this study use a dicho-
tomized APOE ε4 carrier status, being defined as the
presence (1 or 2 copies; APOE ε4 + ve) or absence
(0 copies; APOE ε4-ve) of the ε4 allele. Further, all
analyses for SPON1 rs11023139 (henceforth referred
to as SPON1) were performed based on the dom-
inant model of the minor allele, A, in line with
the findings of the initial GWAS [11]. That is, the
absence of A (SPON1A–; G G) compared with its
presence (SPON1A+; A A, G A). The following
statistical analyses were performed in RStudio (RStu-
dio Team 2015) Version 0.98.1103 for Macintosh
[30]. Analysis of baseline demographic data included
means/counts and standard deviations/percentages
for all variables. To determine whether significant
differences between SPON1A– and SPON1A+ were
present in demographic variables analysis of variance
(ANOVA) and chi-squared tests were used.
To assess the influence of SPON1, A, and APOE
ε4 on longitudinal cognitive performance, linear
mixed-effects (LME) models were performed using
the R “nlme” package. Two planned interactions were
conducted to investigate independent and interac-
tional effects. In all analyses, cognitive composite
scores are included in the models as dependent
variables. In analyses assessing AIBL-PACC age is
included as a covariate in addition to those specif-
ically mentioned below. Initially, a SPON1×Time
interaction was modelled in the complete cognitively
normal sample, controlling for APOE ε4 and A
status. To determine whether there was a modify-
ing effect of SPON1, on A and APOE ε4 mediated
decline, the sample was first stratified by A status.
Following this, an APOE×SPON1×Time interaction
was modelled in each group. All analyses were cor-
rected for the False Discovery Rate (FDR) using
Q-Value (bootstrap method) [31].
RESULTS
SPON1 rs11023139 and cognition in cognitively
normal older adults
Displayed in Table 1 is the demographic infor-
mation for the cognitively normal sample utilized in
the current study stratified by SPON1A carriage. No
significant differences were observed on any demo-
graphic measures, including ε4 carriage (Table 1).
The SPON1A+ group had a higher proportion of
Ahigh individuals, though this did not reach statis-
tical significance (52% versus 42%; p = 0.1575).
When investigating the independent effect of
SPON1, differences in longitudinal cognitive per-
formance between SPON1A+ and SPON1A– were
observed, however these differences did not reach
statistical significance (Table 2, Fig. 1). In the
measure of global cognition (p = 0.075, q = 0.105)
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and verbal episodic memory (p = 0.084; q = 0.114),
decline was observed in the SPON1A+ group, but not
the SPON1A– group, this difference trended towards
significant (Table 2, Fig. 1). No significant differences
are reported in the AIBL-PACC based on carriage of
SPON1A (p = 0.797; Table 2, Fig. 1).
SPON1 rs11023139 and cognition in cognitively
normal older adults stratified by Aβ
In Alow CN older adults, the APOE ε4-ve/
SPON1A+ group declined significantly faster when
compared to APOE ε4-ve/SPON1A– in measures
of global cognition (p = 0.037, q = 0.062) and ver-
bal episodic memory (p = 0.047, q = 0.071; Table 3,
Fig. 2). However, these significances did not sur-
vive correction for the false discovery rate. When
Table 2
Slopes for cognitive composites in cognitively normal older adults
SPON1A– SPON1A+
n = 531 n = 59
  p
Global Cognition 0.030 –0.012 0.075
Verbal Episodic Memory 0.033 –0.007 0.084
AIBL-PACC –0.021 –0.037 0.797
Mean slopes for global cognition (SD/year), verbal episodic
memory (SD/year) and AIBL-PACC (4 × SD/year) in all imaged
cognitively normal participants (n = 590), controlling for APOE
ε4 carrier, amyloid- status and additionally age in AIBL-PACC.
∗Represents a nominally statistically significant difference in slope
of the SPON1A– (G G) group when compared to the SPON1A+
(A A and G A) group. §q < 0.05 for those reporting nominal sig-
nificance at p < 0.05. SPON1, Spondin-1; AIBL-PACC, Australian
Imaging, Biomarkers and Lifestyle Study Pre-Alzheimer’s Cogni-
tive Composite.
investigating Ahigh CN older adults, the APOE
ε4 + ve/SPON1A+ group showed a significantly
greater rate of decline on the global composite
(p = 0.0005, q = 0.004; p = 0.0004 q = 0.004), verbal
episodic memory (p = 0.001, q = 0.006; p = 0.001,
q = 0.005), and the AIBL-PACC (p = 0.030, q = 0.059;
p = 0.019 q = 0.048), over seven and a half years
relative to the APOE ε4-ve/SPON1A– and APOE
ε4-ve/SPON1A+ groups (Table 3, Fig. 2). Simi-
larly, assessment of the APOE ε4 + ve/SPON1A–
group showed a significantly greater rate of decline
on all composites; global (p = 0.007, q = 0.02;
p = 0.021, q = 0.048), verbal episodic memory
(p = 015, q = 0.042; p = 0.027, q = 0.056), and AIBL-
PACC (p = 0.0008, q = 0.005; p = 0.006, q = 0.022),
relative to the APOE ε4-ve/SPON1A– and APOE
ε4-ve/SPON1A+ groups (Table 3, Fig. 2). When com-
pared to the APOE ε4 + ve/SPON1A– group, the
APOE ε4 + ve/SPON1A+ group showed a signifi-
cantly greater rate of decline on the global composite
(p = 0.011, q = 0.033), and verbal episodic memory
(p = 0.020, q = 0.048; Table 3, Fig. 2).
DISCUSSION
While this study did not observe an independent
association between SPON1 and cognitive decline
in a preclinical AD sample, as previously reported
[11], the hypothesis that SPON1 modifies A and
APOE ε4 driven cognitive decline in the preclini-
cal stages of AD was supported. However, whilst
Sherva and colleagues [11] reported that carriage
of the minor allele of rs11023139 (SPON1A+) was
Fig. 1. Rates of change in cognitively normal older adults. Rates of change are presented for (a) global cognition (SD/year), (b) verbal episodic
memory (SD/year) and (c) AIBL-PACC (4 × SD/year) in cognitively normal older adults (n = 590). SPON1A– (grey) and SPON1A+ (black).
Controlling for APOE ε4 and amyloid- status, AIBL-PACC analysis also controlled for age. Error bars represent time dependent standard
error, ∗p < 0.05.
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Table 3
Slopes for cognitive composites in cognitively normal older adults stratified by amyloid-, APOE ε4 interaction
APOE ε4-ve / APOE ε4-ve / APOE ε4 + ve / APOE ε4 + ve /
SPON1A– SPON1A+ SPON1A– SPON1A+
   
Alow n = 255 n = 23 n = 53 n = 5
Global Cognition 0.057 –0.011∗ 0.050 –0.021
Verbal Episodic Memory 0.059 –0.005∗ 0.051 –0.031
AIBL-PACC 0.051 –0.059 0.062 0.095
Ahigh n = 123 n = 22 n = 100 n = 9
Global Cognition 0.014 0.043 –0.058∗†§ –0.263∗†‡§
Verbal Episodic Memory 0.017 0.049 –0.045∗†§ –0.217∗†‡§
AIBL-PACC 0.088 0.169 –0.152∗†§ –0.375∗†§
Mean slopes for global cognition (SD/year), verbal episodic memory (SD/year) and AIBL-PACC (4 × SD/year)
in imaged cognitively normal adults with low (n = 336) or high (n = 254) amyloid-. Controlling for age in AIBL-
PACC. ∗p < 0.05 when comparing to the APOE ε4-ve/SPON1A–group, †p < 0.05 when comparing to the APOE
ε4-ve/SPON1A+group, ‡p < 0.05 when comparing to the APOE ε4 + ve/SPON1A–. §q < 0.05 for those reporting
nominal significance at p < 0.05. SPON1, Spondin-1; APOE, Apolipoprotein E; A, Amyloid-; AIBL-PACC,
Australian Imaging, Biomarkers and Lifestyle Study Pre-Alzheimer’s Cognitive Composite.
Fig. 2. Rates of change in cognitively normal adults stratified by amyloid- status, APOE ε4 interaction. Rates of change are presented for
(a, d) global cognition (SD/year), (b, e) verbal episodic memory (SD/year) and (c, f) AIBL-PACC (4 × SD/year) in cognitively normal older
adults with low (a, b, c; n = 336) or high (d, e, f; n = 254) amyloid-. APOE ε4-ve/SPON1A– (green), APOE ε4-ve/SPON1A+ (blue), APOE
ε4 + ve/SPON1A– (orange), APOE ε4 + ve/SPON1A+ (red). Controlling for age in AIBL-PACC. Error bars represent time dependent standard
error. ∗p < 0.05 when comparing to the APOE ε4-ve/SPON1A– carrier group, †p < 0.05 when comparing to the APOE ε4-ve/SPON1A+ group,
‡p < 0.05 when comparing to the APOE ε4 + ve/SPON1A– carrier.
associated with slower decline in advanced stages
of AD, the opposite was observed, though in pre-
clinical AD, in the current study. Specifically, whilst
no significant associations were observed in Alow
individuals for the assessment of the combinatory
effect of A, APOE ε4, and SPON1 on cogni-
tive decline, in the Ahigh CN older adults both
APOE ε4 + ve groups had significantly increased
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rates of decline when compared to the APOE ε4-ve
groups in all measures of cognition. Further, within
Ahigh CN older adults, global cognition and ver-
bal episodic memory declined significantly faster in
the APOE ε4 + ve/SPON1A+ group when compared
to the APOE ε4 + ve/SPON1A– group. These results
suggest that at the preclinical stages of AD, carriage
of SPON1A+ increases rates of decline, in these mea-
sures of cognition, beyond what is expected by the
carriage of APOE ε4 alone.
Several studies suggest that Spondin-1 may play
a role in AD pathogenesis. In vivo screening identi-
fied Spondin-1 as a protein that interacts with APP
[17]. It has been reported to interact with APP,
thereby regulating beta-secretase of APP [18]. Hoe
et al. published an interaction between Spondin-1
and, APP and ApoE receptor 2 [32]. This interac-
tion was reported to result in the increased cleavage
of APP and ApoE receptor-2, which was speculated
by the authors to result in reduced A production
[32]. The overexpression of Spondin-1 in mice has
been associated with improvements in cognition [16,
33], particularly spatial learning and memory [16].
Spondin-1 overexpression has also been associated
with reduction in A plaque deposition in in vivo
mouse models [16] and reduced A in in vitro murine
neural cell models [33]. However, despite these find-
ings, another study has reported increased levels of
Spondin-1 in the cerebrospinal fluid (CSF) of AD
patients when compared to healthy controls [34]. The
biological effects exhibited by Spondin-1 support the
hypothesis that genetic variation may moderate the
AD pathogenesis, the impact of genetic variation in
SPON1 on gene expression and protein function are
largely unknown, though a variant (rs2618516) has
been associated with patterns of brain connectivity in
young adults [35] and subsequent impact on severity
of AD [35] and cognitive performance in APOE ε4
carriers [36]. However, this variant is not in complete
linkage disequilibrium as has very low correlation
(D’ = 0.45, r2 = 0.006) with the variant investigated
by Sherva and colleagues [11] and this study. As such,
studies aimed at increasing the understanding of the
specific functional effects of genetic variants would
be an important next step.
There are several factors that may have contributed
to the contradictory allelic associations reported in
preclinical AD, in the current study, and in more
advanced stages, by Sherva and colleagues [11]. The
differences in the stages of the disease studied may
be one factor contributing to the contrasting asso-
ciations reported here. Cognitive assessments at the
preclinical stages of AD are less likely to be signif-
icantly confounded by consequent disease processes
and other factors that may reduce sensitivity or reli-
ability of cognitive assessments, such as diminished
intellectual ability or floor effects of cognitive assess-
ments that may occur when assessing advanced stages
of AD. A further factor may be the inclusion of brain
A status in analyses. The current study found asso-
ciations with cognitive decline in Ahigh CN older
adults who were APOE ε4 + ve, whilst A status
was not included in the original analyses and there-
fore the AD diagnosis was not confirmed by imaging
findings. Finally, the duration over which cognitive
decline was assessed, in addition to the cognitive
assessment themselves, were significantly different.
The current study used a combination of assessments
over a 90-month period, with 18-months between
visits, to define composite measures of function
compared to the ADAS-Cog over only 24 (AD par-
ticipants) to 48-months (mildly cognitively impaired
participants), with 6 to12-months between visits.
These factors, when combined with rs11023139’s
minor allele frequency of approximately 5% may
explain the disparate associations. Overall, the find-
ings presented in this study provide further evidence
to support the role of genetics in contributing to vari-
able rates of cognitive decline seen at the preclinical
stages of AD. While the clinical relevance of this
SPON1 variant in isolation may be limited due to its
minor allele frequency, we have previously reported
its predictive role in combination with other genetic
variants, particularly when weighted by their impact
on cognitive decline [27, 29].
Whilst this study uses a highly characterized longi-
tudinal cohort, the following limitations are acknowl-
edged. The AIBL cohort, like ADNI, represent a
predominantly Caucasian population, thus the find-
ings from these studies should be replicated in
additional ethnically diverse cohorts to gain a broader
understanding of the SPON1 rs11023139 associa-
tions. Additionally, the voluntary nature of the AIBL
Study has resulted in a cohort that is highly educated;
therefore, the observations made here may only be
observable in similar cohorts. Due to the unavail-
ability of sufficient tau imaging or CSF data for
participants in this study, the definition of preclinical
AD was based on NIA-AA recommended criteria [4]
rather than more recent criteria that includes amyloi-
dosis, tau and neurodegeneration. This study focused
particularly on cognitive changes that occur early
in the disease process through the use of cognitive
composite scores. Different findings may result from
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the use of different cognitive assessments in the cal-
culation of composite scores or when using single
cognitive assessments and when assessing differ-
ent cognitive domains. Finally, as alluded to earlier,
rs11023139 has a minor allele frequency of approx-
imately 0.05, resulting in small sample sizes for the
groups, most notably after interactions with A and
APOE ε4, possibly influencing the results. The results
reported here should be replicated in other preclini-
cal AD cohorts with A imaging and longitudinal
cognitive data comparative to what is utilized here.
CONCLUSIONS
The results presented in this study are to our knowl-
edge the first to attempt replicate the findings in
the ADNI GWAS implicating SPON1A+ with cog-
nitive function. This is the first study to observe
an effect of the interaction of A, APOE ε4, and
SPON1 on cognitive performance in a cohort of CN
older adults. Reported here are results implicating
SPON1 rs11023139 as factor in preclinical cogni-
tive decline. Investigation into the possible functional
mechanisms of SPON1 rs11023139 is required to
properly understand its influence over A and APOE
ε4 mediated cognitive decline. However, this study
does provide additional strong evidence for the study
of genetic variation with respect to cognitive rates of
change at the earliest stages of AD.
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